SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

Sanofi - ADR

Sanofi-Aventis

Sanofi ($SNY) is trending amidst discussions of potential acquisitions and partnerships, particularly fueled by speculation from the Altimmune ($ALT) community regarding a possible buyout.  The community is weighing the potential benefits of partnerships with companies like $VKTX and $GUTS, while keeping a close eye on developments in the broader pharmaceutical sector and competitive dynamics with companies like $LLY and $NVO.

The Stellar network is an open source, distributed, and community owned network used to facilitate cross-asset transfers of value. Stellar aims to help facilitate cross-asset transfer of value at a fraction of a penny while aiming to be an open financial system that gives people of all income levels access to low-cost financial services. Stellar can handle exchanges between fiat-based currencies and between cryptocurrencies. Stellar.org, the organization that supports Stellar, is centralized like XRP and meant to handle cross platform transactions and micro transactions like XRP. However, unlike Ripple, Stellar.org is non-profit and their platform itself is open source and decentralized.   Stellar was founded by Jed McCaleb in 2014. Jed McCaleb is also the founder of Mt. Gox and co-founder of Ripple, launched the network system Stellar with former lawyer Joyce Kim. Stellar is also a payment technology that aims to connect financial institutions and drastically reduce the cost and time required for cross-border transfers. In fact, both payment networks used the same protocol initially.  Distributed Exchange Through the use of its intermediary currency Lumens (XLM), a user can send any currency that they own to anyone else in a different currency.  For instance, if Joe wanted to send USD to Mary using her EUR, an offer is submitted to the distributed exchange selling USD for EUR. This submitted offer forms is known as an order book. The network will use the order book to find the best exchange rate for the transaction in-order to minimize the fee paid by a user.  This multi-currency transaction is possible because of "Anchors". Anchors are trusted entities that hold people’s deposits and can issue credit. In essence, Anchors serves as the bridge between different currencies and the Stellar network.  Lumens (XLM) Lumens are the native asset (digital currency) that exist on the Stellar network that helps to facilitate multi-currency transactions and prevent spams. For multi-currency transactions, XLM is the digital intermediary that allows for such a transaction to occur at a low cost.  In-order to prevent DoS attacks (aka spams) that would inevitably occur on the Stellar network, a small fee of 0.00001 XLM is associated with every transaction that occurs on the network. This fee is small enough so it does not significantly affect the cost of transaction, but large enough so it dissuades bad actors from spamming the network.   Prior to Protocol 12, Stellar had a built-in inflation mechanism conceived to allow account holders to collectively direct inflation-generated lumens toward projects built on Stellar.  As the network evolved and grew, it became increasingly clear that inflation wasn’t working as intended — account holders either didn’t set their inflation destination or joined inflation pools to claim the inflation themselves, and the operational costs associated with inflation payments continued to rise — and so a protocol change to disable inflation was proposed, implemented, voted on by validators, and ultimately adopted as part of a network upgrade.  The inflation operation is now deprecated. https://developers.stellar.org/docs/glossary/inflation/

Stellar Lumens

XLM is trending amidst market volatility, with community members actively discussing potential accumulation opportunities and key support levels. Some traders are speculating on short-term price movements, while others maintain a long-term bullish outlook, emphasizing utility and future potential. Recent news around treasury initiatives and partnerships may also be contributing to the increased attention.

Sound Group, Inc. is global audio-centric social and entertainment company, which engages in the provision of an audio platform. It focuses on audio entertainment and social networking. The company was founded by Jinnan Lai and Ning Ding in November 2010 and is headquartered in Singapore.

Sound Group Inc - ADR

Sound Group Inc

Sound Group Inc ($SOGP) is trending amid discussions around option trading and potential for high ROI, with some traders pointing to actionable alerts for both calls and puts. While some community members express bullish sentiment with mentions of gearing up, buy zones, and positive earnings growth, others warn of potential pump-and-dump schemes due to its history and association with Asian-based companies. The stock's volatility and past performance are also being heavily debated.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox is trending downwards as concerns emerge regarding decelerating growth in core markets and some analysts pointing to an unstable "boom-bust viral hit model". Despite strong user engagement and platform growth, the stock faces scrutiny over profitability and rising expenses, leading to a mixed sentiment among investors. Additionally, concerns about child safety and potential legal hurdles contribute to the negative pressure.

Bath & Body Works, Inc. is a specialty retailers and home to America’s Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap. The company was founded by Leslie Herbert Wexner in 1963 and is headquartered in Columbus, OH.

Bath & Body Works Inc

BBWI is trending due to a mix of factors, including recent analyst upgrades, strong Q3 earnings, and raised full-year guidance. The community is discussing whether the recent surge is justified and if the stock is undervalued given its low P/E ratio and growth potential. Bullish sentiment is building around holiday sales expectations and the company's strategic initiatives, though some remain cautious.

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals ($IONS) is trending, fueled by positive results for donidalorsen in hereditary angioedema (HAE) trials, sparking optimism about its potential as a best-in-class treatment.  The community is actively discussing the drug's efficacy and its competitive edge against existing therapies like Orladeyo. Bullish sentiment is building, with some analysts raising price targets.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bear 3X Shares

LABD is trending as the underlying, XBI, approaches multi-year highs, causing concern for current LABD holders. The community is discussing strategies for managing downside risk and potential exit points, with some expressing frustration. Traders are watching for a potential reversal, influenced by factors like earnings, trade tensions, and Fed policy.

BlackPearl.Chain is pushing decentralization into the future with a third-generation public blockchain. It’s network achieves blazing transaction speeds (Millions TPS) using Sharding and a VRF lightning-fast consensus mechanism built in-house. Finality is achieved in under three seconds with revolutionary P2P, Its speed and security make it the perfect platform for applications like digital asset trading, social media messaging, payment processing, supply chain tracking, and other high-scale use cases.

BlackPearl

BlackPearl (BPLC) is trending as community members express strong conviction in its long-term potential and future listings on major exchanges. Optimism is fueled by the project's team and perceived potential within the banking and monetary system, with some anticipating significant market cap growth. The conversation highlights both excitement for immediate gains and a belief in the project's long-term investment viability.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify is trending due to community discussion around its Q3 earnings, which revealed subscriber growth and new pricing tiers, although some express concerns about valuation. The community is actively debating the impact of these changes on the company's future profitability and its competitive positioning against rivals like YouTube Music. Additionally, a newly announced partnership with Netflix to offer video podcasts has sparked discussions around content strategy and subscriber engagement.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain and as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is experiencing heightened interest, with community members actively discussing recent price pumps and dumps, as well as the potential impact of the upcoming Goliath mainnet launch and staking rewards. Some traders express concerns about manipulation, while others remain optimistic about long-term growth and potential partnerships. The delisting of Binance futures seems to have removed a big obstacle to price discovery.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Agios Pharmaceuticals, Inc. $AGIO Shares Acquired by CenterBook Partners LP

CenterBook Partners LP increased its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 124.0% during the 2nd quarter, according to its most recent 13F filing with the Securities...

Agios Pharmaceuticals (NASDAQ:AGIO) Given New $20.00 Price Target at JPMorgan Chase & Co.

JPMorgan Chase & Co. dropped their price objective on shares of Agios Pharmaceuticals from $37.00 to $20.00 and set a "neutral" rating for the company in a research note on Friday...

Agios Pharmaceuticals (NASDAQ:AGIO) Cut to Sell at Wall Street Zen

Wall Street Zen cut Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday...

Agios Pharmaceuticals (NASDAQ:AGIO) Sees Strong Trading Volume After Analyst Upgrade

Agios Pharmaceuticals (NASDAQ:AGIO) Sees Unusually-High Trading Volume After Analyst Upgrade...

HC Wainwright Lowers Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $48.00

HC Wainwright lowered their price objective on Agios Pharmaceuticals from $56.00 to $48.00 and set a "buy" rating for the company in a research report on Thursday...

Agios Pharmaceuticals (NASDAQ:AGIO) Cut to "Sector Perform" at Royal Bank Of Canada

Royal Bank Of Canada cut Agios Pharmaceuticals from an "outperform" rating to a "sector perform" rating and set a $28.00 target price on the stock. in a report on Wednesday...

AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results

Agios slides to a 52-week low after mixed phase III RISE UP data show a hemoglobin boost but no significant cut in pain crises.

Stock Traders Purchase High Volume of Agios Pharmaceuticals Call Options (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock traders bought 8,407 call options on the stock. This is...

Agios Pharmaceuticals (NASDAQ:AGIO) Sets New 12-Month Low - Here's Why

Agios Pharmaceuticals (NASDAQ:AGIO) Hits New 1-Year Low - Here's What Happened...

<ul class="summary-bullets"><li>Mitapivat met the hemoglobin endpoint but missed the endpoints for pain crises and fatigue, prompting concerns about the mixed Phase 3 readout.</li><li>BofA, RBC, and H.C. Wainwright cut price targets, flagging a more uncertain path toward potential FDA approval.</li><li>Stocktwits traders debated the drop, with some buying the dip ahead of the upcoming FDA submission timeline.</li></ul>Agios Pharmaceuticals, Inc. shares crashed to their worst session on record on Wednesday after the company reported mixed late-stage trial results for its sickle cell disease treatment, triggering a wave of sharply lower analyst price targets.The stock closed down 51% at $22.34 before edging up 0.9% in after-hours trading.<h2 class="st-heading-2">Wall Street Turns Cautious</h2>Bank of America Securities (BofA) lowered the firm’s price target to $32 from $54 and maintained a 'Buy' rating. The note said the RISE UP study showed mitapivat met the primary hemoglobin endpoint but delivered “only modest directional benefit” for sickle cell pain crises and fatigue. While the company has previously said that hitting either primary endpoint would be sufficient for approval, BofA wrote that the results now point to “an uncertain regulatory and commercial path forward.”RBC Capital took a more cautious stance, downgrading Agios to 'Sector Perform' from 'Outperform' and slashing its target to $28 from $57. The firm wrote that although mitapivat is “clearly active,” it “fell short on the most important endpoints for patients,” noting gaps in crisis reduction, hospitalization, and fatigue. RBC said the changes reflect lower odds of success for the sickle cell program and reduced potential uptake even if the drug is ultimately approved.H.C. Wainwright also lowered its target to $48 from $56, while reiterating a 'Buy' rating. The firm called the market reaction “overdone” and said it remains “cautiously optimistic” about eventual FDA approval, citing the Oxbryta precedent and the absence of new safety issues, though it acknowledged that the data “increase some uncertainty.”<h2 class="st-heading-2">Trial Results&nbsp;</h2>The Wave of analyst downgrades came after Agios released topline data from its Phase 3 RISE UP study in sickle cell disease, the larger of its two key readouts before year-end 2025. The company reported that mitapivat met the primary endpoint of hemoglobin response, achieving a statistically significant improvement compared with placebo. It also showed positive effects on hemoglobin concentration and indirect bilirubin levels.However, Agios said the study did not show a statistically significant reduction in sickle cell pain crises and reported no improvement in fatigue, an important quality-of-life measure for patients. Agios plans to share the full clinical program with the FDA in the first quarter of 2026 as it prepares to pursue potential U.S. approval.<h2 class="st-heading-2">Competitors Gain On Agios Miss</h2>Leerink said that early Phase 1b data for Fulcrum Therapeutics’ pociredir suggest a “potentially differentiated and favorable efficacy profile” compared with mitapivat, noting the limits of direct comparison. Oppenheimer said the Agios outcome may be viewed as removing competitive pressure for Fulcrum, adding that the RISE UP results resembled HOPE, with marginal improvements in hemoglobin and no statistical significance for vaso-occlusive crises. The firm reiterated an 'Outperform' rating on Fulcrum.<h2 class="st-heading-2">Stocktwits Traders Eye FDA Date</h2>On Stocktwits, retail sentiment for Agios was ‘extremely bullish’ amid a 6,400% surge in 24-hour message volume.<figure class="image"><img style="aspect-ratio:971/140;" src="https://news.stocktwits-cdn.com/agio_ss_png_9b70c6d993.webp" alt="agio ss.png" width="971" height="140"><figcaption>AGIO sentiment and message volume as of November 21 | Source: Stocktwits</figcaption></figure>One user said, “I'll load more tomorrow and Friday. Need to be ready for December 6th FDA approval. Should skyrocket!!!”<stembedurl>https://stocktwits.com/murphylaw/message/636840528</stembedurl>Another user argued the selloff was excessive, saying the strong hemoglobin response and clean safety profile still supported a viable approval path, adding that one missed endpoint was unlikely to derail progress and that "it doesn’t take a perfect score for approval."<stembedurl>https://stocktwits.com/Mr_patience_MAN/message/636821985</stembedurl><a href="https://stocktwits.com/symbol/AGIO">Agios’ stock</a> has declined 51% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Agios Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Agios Pharmaceuticals Stock Suffers Record Wipeout As Wall Street Warns Of 'Uncertain' Regulatory Path For Sickle Cell Drug

Mitapivat met the hemoglobin endpoint but missed the endpoints for pain crises and fatigue, prompting concerns about the mixed Phase 3 readout.

Equity

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Current Price	$25.24
Prev Close	$24.57
Open	$24.66
Dividend Yield	0.00%
50-Day Moving Average	$39.91
Beta	1.14
Avg. Volume	552,851.22
PE Ratio	-3.63

52-Week High	$62.45
52-Week Low	$22.24
Market Capitalization	$1.87B
EPS (Annual)	$11.64
Price to Book	1.15
Revenue Per Employee	$74,790.98
Enterprise Value/EBITDA	N/A

AGIO
Agios Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AGIO News

AGIOAgios Pharmaceuticals Inc